ID: ALA3343945

Max Phase: Preclinical

Molecular Formula: C30H19FN2O4S

Molecular Weight: 522.56

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)c1cccc(-c2ccc(/C=c3\sc4n(c3=O)C(c3ccc(F)cc3)C=C(c3ccccc3)N=4)o2)c1

Standard InChI:  InChI=1S/C30H19FN2O4S/c31-22-11-9-19(10-12-22)25-17-24(18-5-2-1-3-6-18)32-30-33(25)28(34)27(38-30)16-23-13-14-26(37-23)20-7-4-8-21(15-20)29(35)36/h1-17,25H,(H,35,36)/b27-16-

Standard InChI Key:  JAFVLZFGBZDIEY-YUMHPJSZSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 522.56

Molecular Weight (Monoisotopic): 522.1050

AlogP: 5.10

#Rotatable Bonds: 5

Polar Surface Area: 84.80

Molecular Species: ACID

HBA: 6

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.72

CX Basic pKa: 4.52

CX LogP: 5.56

CX LogD: 3.19

Aromatic Rings: 5

Heavy Atoms: 38

QED Weighted: 0.35

Np Likeness Score: -1.03

References

1. Zhao D, Chen C, Liu H, Zheng L, Tong Y, Qu D, Han S..  (2014)  Biological evaluation of halogenated thiazolo[3,2-a]pyrimidin-3-one carboxylic acid derivatives targeting the YycG histidine kinase.,  87  [PMID:25282671] [10.1016/j.ejmech.2014.09.096]

2. Vo CD, Shebert HL, Zikovich S, Dryer RA, Huang TP, Moran LJ, Cho J, Wassarman DR, Falahee BE, Young PD, Gu GH, Heinl JF, Hammond JW, Jackvony TN, Frederick TE, Blair JA..  (2017)  Repurposing Hsp90 inhibitors as antibiotics targeting histidine kinases.,  27  (23): [PMID:29110989] [10.1016/j.bmcl.2017.10.036]

Source

Source(1):

• Scientific Literature